argenx SE achieved sales of $1.13 billion in the three months ended 30 September, a quarterly record for the company which has successfully exploited the therapeutic potential of a single biologic asset. Announced on 30 October, the quarterly sales were nearly double the $573 million generated a year earlier. They were helped by high demand for a prefilled syringe formulation of the lead product Vyvgart (efgartigimod). Vyvgart binds to the neonatal Fc receptor (FcRn), which is responsible for maintaining the circulation of immunoglobuline G (IgG) in the body.
